- Home
- / Altamira Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Altamira Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2.2
2021-09-22
Market Capitalization
$39.2 M
2021-09-22
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CHF | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 64.0K | 306.0K | 158.0K | ||||
| Cost of goods sold | 2.2M | 1.4M | 192.0K | ||||
| Gross profit | 176.0K | (1.7M) | (428.0K) | 354.0K | 75.0K | ||
| Gross profit margin, % | 224.1% | ||||||
| Operating expense total | 11.4M | 7.2M | 5.7M | 13.8M | 13.1M | 7.9M | 6.8M |
| Depreciation and amortization | 73.0K | 31.0K | 20.0K | 1.6M | 12.6M | 119.0K | 127.0K |
| EBITDA | (11.4M) | (7.2M) | (5.5M) | (15.5M) | (13.5M) | (7.6M) | (7.5M) |
| EBITDA margin, % | -4817.7% | ||||||
| EBIT | (11.5M) | (7.3M) | (5.5M) | (17.1M) | (26.1M) | (2.5M) | (7.6M) |
| EBIT margin, % | -1598.1% | ||||||
| Interest income | 18.0K | 3.0K | 1.0K | 302.0K | 3.0K | ||
| Interest expense | 1.1M | 29.0K | 135.0K | 190.0K | 912.0K | 1.2M | 260.0K |
| Pre tax profit | (11.3M) | (6.8M) | (8.2M) | (17.4M) | (26.5M) | (4.0M) | (8.5M) |
| Income tax expense | 162.0K | (194.0K) | (21.0K) | 22.0K | (10.0K) | (100.0K) | |
| Net Income | (11.5M) | (6.6M) | (8.2M) | (17.4M) | (26.5M) | (3.9M) | (8.5M) |